title: Infliximab-induced lupus-like syndrome associated with autoimmune hepatitis.
authors.forename: M
authors.initials: M
authors.lastname: Marques
authors.forename: F
authors.initials: F
authors.lastname: Magro
authors.forename: H
authors.initials: H
authors.lastname: Cardoso
authors.forename: F
authors.initials: F
authors.lastname: Carneiro
authors.forename: R
authors.initials: R
authors.lastname: Portugal
authors.forename: J
authors.initials: J
authors.lastname: Lopes
authors.forename: C
authors.initials: C
authors.lastname: Costa Santos
mesh_terms: D000328:Adult; D000893:Anti-Inflammatory Agents / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D001706:Biopsy; D003093:Colitis, Ulcerative / Q000188:drug therapy; D003937:Diagnosis, Differential; D005260:Female; D019693:Hepatitis, Autoimmune / Q000209:etiology* / Q000473:pathology; D006801:Humans; D000069285:Infliximab; D008099:Liver / Q000473:pathology; D008177:Lupus Vulgaris / Q000139:chemically induced* / Q000175:diagnosis; D013577:Syndrome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab